Open, multicenter Phase II clinical study for the efficacy and safety of BEBT-908 in the treatment of recurrent or refractory diffuse large b-cell lymphoma
Latest Information Update: 13 Oct 2023
At a glance
- Drugs BEBT 908 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors BeBetter Med
Most Recent Events
- 08 Oct 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Apr 2023 New trial record
- 22 Dec 2021 According to BeBetter Med media release, Guangzhou BeBetter Medicine Technology changed its name to BeBetter Med.